GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (NYSE:OGN) » Definitions » Cash Conversion Cycle

Organon (Organon) Cash Conversion Cycle : 104.87 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Organon Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Organon's Days Sales Outstanding for the three months ended in Dec. 2023 was 96.85.
Organon's Days Inventory for the three months ended in Dec. 2023 was 167.07.
Organon's Days Payable for the three months ended in Dec. 2023 was 159.05.
Therefore, Organon's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 104.87.


Organon Cash Conversion Cycle Historical Data

The historical data trend for Organon's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organon Cash Conversion Cycle Chart

Organon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial 199.68 196.52 84.38 37.04 84.51

Organon Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.21 86.30 103.34 114.85 104.87

Competitive Comparison of Organon's Cash Conversion Cycle

For the Drug Manufacturers - General subindustry, Organon's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organon's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organon's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Organon's Cash Conversion Cycle falls into.



Organon Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Organon's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=93.8+168.2-177.49
=84.51

Organon's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=96.85+167.07-159.05
=104.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Organon  (NYSE:OGN) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Organon Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Organon's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Organon (Organon) Business Description

Traded in Other Exchanges
Address
30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada.
Executives
Kirke Weaver officer: Gen. Counsel & Corp. Secy. 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Ma. Fatima Francisco director ONE PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Deborah H Telman officer: General Counsel 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kathryn Dimarco officer: Corporate Controller 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Susanne Fiedler officer: Chief Commercial Officer 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Vittorio Nisita officer: Head of Global Business Svcs 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Morrissey Joseph T. Jr. officer: Head of Manufacturing 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Aaron Falcione officer: Chief Human Resources Officer 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Deborah R Leone director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Martha E Mcgarry director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Phillip Ozuah director 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Geralyn S Ritter officer: Hd of Ext. Affairs and ESG 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sandra Milligan officer: Head of Research & Development 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Cynthia M Patton director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Alan Ezekowitz director C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139